Vitality Watch

Dossier rss preclinical 30-sep-2026
Animal model, organoid, or cell-culture result — not yet human

Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization

Key claim: Parthenolide targeting of Ero1L alleviates cellular senescence and fibrosis in localized scleroderma by stabilizing mitochondria-associated endoplasmic reticulum membranes.

Abstract

Aging Cell, Volume 25, Issue 10, October 2026.

Why this matters

Localized scleroderma has lacked disease-modifying therapy, and this finding offers a mechanistic candidate — parthenolide-mediated Ero1L inhibition stabilizing mitochondria-associated ER membranes — that pulls together three threads already active in the mechanism vault (senescence, mitochondrial dysfunction, and MAM contact-site biology) into one druggable node. It also extends the parthenolide/feverfew narrative, previously tracked mainly for NF-κB and anti-cancer activity, into a senescence-and-fibrosis-of-aging frame, while leaving the biology-to-pitch gap wide: the data are preclinical scleroderma models, not healthspan.

Source

Link

Briefing card

Targeting Ero1L by Parthenolide Alleviates Cellular Senescence and Fibrosis of Localized Scleroderma by Regulating Mitochondria‐Associated Endoplasmic Reticulum Membranes Stabilization
Stage: preclinical · rss · 30-sep-2026

If you follow parthenolide as a longevity candidate, the supporting evidence is still preclinical — a cell and animal mechanism in scleroderma, not a human outcome.

Parthenolide targeting of Ero1L alleviates cellular senescence and fibrosis in localized scleroderma by stabilizing mitochondria-associated endoplasmic reticulum membranes.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://onlinelibrary.wiley.com/doi/10.1111/acel.70738?af=R

build build 880 · 2bcef25 · 2026-11-18